Elicio Therapeutics, a biotech company developing immunotherapies for KRAS-driven cancers, was added to the Russell 2000 and Russell 3000 indexes as of June 26, 2026. This inclusion marks a milestone reflecting growing recognition of Elicio's advancements, particularly with its lead product ELI-002 7P targeting KRAS mutations in cancers like pancreatic and colorectal cancer. The company plans to advance clinical trials, including a Phase 1 study in metastatic pancreatic cancer, aiming to improve treatment strategies and expand indications. Being part of these indexes increases Elicio's visibility among institutional investors and supports its commitment to delivering value to patients and shareholders.
Volaris Group has acquired SureView Systems, a UK company specializing in enterprise security monitoring and response software for physical and cyber domains. This acquisition enhances Volaris's security vertical by adding SureView's expertise in phy...
Skanska USA has appointed Bryan Northrop as executive vice president and general manager of its Advanced Technology unit, effective July 1. Northrop will oversee construction projects related to semiconductors and data centers across multiple states,...
Caribou Biosciences, a clinical-stage CRISPR biopharma company, announced that CEO Rachel Haurwitz will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. The event highlights Caribou's ...
Kaltura has been recognized as a Representative Vendor in the 2026 Gartner Market Guide for Video Platform Services for the second consecutive year. The company offers AI-driven video platform services that transform video into interactive, intellige...
A proposed $18.9 million class action settlement has been approved by a U.S. District Court for investors who purchased Biogen Inc. common stock between June 8 and July 12, 2021. The settlement aims to resolve claims against Biogen and certain execut...
